= Solution
\b[These pathways are tractable at several distinct levels, but selective <target engagement> and a useful <therapeutic window> must both be demonstrated.] A <G protein-coupled receptor> acts as a <guanine nucleotide exchange factor> for a <heterotrimeric G protein>: release of <GDP> permits <GTP> binding, changing the interactions of both the <G protein alpha subunit> and <Gβγ> with effectors. <GTPase-activating proteins>, including regulators of <G protein> signalling, accelerate return to the <GDP>-bound state. <Gαs> can stimulate <adenylyl cyclase>, <Gαi> can inhibit it, and <Gαq> can activate <phospholipase C>, linking receptor occupancy to different intracellular responses. The related <small GTPases>, such as <Ras>, also alternate between <GDP>- and <GTP>-bound states, but are monomeric switches with different activators and effectors. Strategies effective against one family cannot simply be assumed to work against the other.
The receptor is often the most accessible intervention point. An <orthosteric antagonist> competes with the endogenous <ligand>; an <agonist> activates a deficient response, while a <partial agonist> can produce an intermediate response and antagonize a higher-efficacy <agonist>. For example, <beta-adrenergic receptor> blockade reduces adrenergic stimulation of the heart. However, conserved binding pockets make receptor-subtype selectivity difficult, and the same receptor can have useful and harmful functions in different tissues. An <allosteric modulator> binds elsewhere and changes the affinity or efficacy of the endogenous <ligand>. This can exploit a less conserved pocket and preserve the timing of endogenous release; it does not automatically confer tissue specificity or a ceiling on toxicity. Structural studies of the <beta-2 adrenergic receptor> show why stabilizing particular receptor conformations can change coupling rather than merely change occupancy.<Structural insights into the dynamic process of β2-adrenergic receptor signaling by Aashish Manglik and others>[Conformational intermediates examined by spectroscopy]{ref}
<biased agonism> aims to favour one signalling output over another, for example <G protein> activation relative to <arrestin> recruitment. An opioid study found that <TRV130> combined analgesia with reduced respiratory and gastrointestinal effects in rodent comparisons with morphine.<A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine by Scott M. DeWire and others>[Preclinical signalling and equianalgesic comparisons]{ref} The inference that bias itself causes improved safety requires caution: different assays have different amplification and <receptor reserve>. Later direct measurements showed that low intrinsic <G protein> efficacy can explain favourable profiles of several proposed biased opioids.<Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists by Alexander Gillis and others>[Comparison of intrinsic efficacy and apparent bias]{ref} A convincing experiment therefore compares <ligands> with a common reference, matched receptor abundance and time courses, and proximal measurements of both pathways; it then tests benefit and toxicity at comparable effective exposures. An <arrestin> recruitment assay alone cannot predict an entire clinical adverse-effect profile.
Direct inhibition of the switch is also possible. Competing at a nucleotide-binding site is difficult because intracellular <nucleotides> are abundant and binding is tight. Nevertheless, an alternative pocket can trap a particular state. <YM-254890> binds an interdomain cleft of <Gαq> and inhibits nucleotide exchange by stabilizing the <GDP>-bound arrangement. Structural analysis, exchange measurements and tests against other <G protein> families connect binding to mechanism, rather than inferring <Gαq> inhibition from a fall in a distant calcium response.<Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule by Akiyuki Nishimura and others>[Structure and biochemical inhibition of GDP release]{ref} This illustrates chemical tractability, although inhibiting a widely used Gα family could impair normal signalling in many tissues. Targeting an interaction with a particular receptor, exchange factor or effector may give greater contextual selectivity.
A complementary example is covalent inhibition of mutant <Ras>. <AMG 510> exploits a pocket adjacent to cysteine 12 in <KRAS G12C> and favours the inactive <GDP>-bound <protein>. Its mutant-selective chemistry avoids requiring a nucleotide competitor, and biochemical, cellular and animal experiments connected the compound with suppression of signalling and tumour growth.<The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity by Jude Canon and others>[Mutant-selective binding and antitumour experiments]{ref} This solution depends on the reactive cysteine and the accessibility of the trapped state; it is not a universal inhibitor of all <Ras> <mutations>. Exchange activity, pathway feedback, alternative signalling and additional <mutations> can change sensitivity. Moreover, a monomeric <Ras> inhibitor is evidence about a broader GTPase strategy, not evidence that all <heterotrimeric G proteins> have equivalent pockets.
Other possible interventions include blocking selected <Gβγ>–effector contacts, enhancing a suitable <GTPase-activating protein>, preventing <cell membrane> recruitment, or inhibiting a downstream <enzyme>. Each trades accessibility against specificity: a downstream convergence point can bypass an inaccessible upstream lesion, but may suppress useful signals from many receptors. To select between these strategies, establish the disease-dependent molecular state, measure direct binding and exchange or <hydrolysis>, and confirm the predicted proximal output. Use an inhibitor-resistant rescue allele, an isogenic target-negative control, and counterscreens against related switches and unrelated cytotoxicity. Follow this with <target engagement> in the relevant tissue and measurements of normal physiological responses. \b[The strongest therapeutic case combines a drug-accessible pocket or interface with a disease-specific dependence; pathway membership alone is insufficient.]
Back to article page
